VIVEbiotech achieves significant business growth in 2023 with increases in demand for its lentiviral vector specialization and capabilities

VIVEbiotech announces significant growth in 2023, with sales increasing by 70%.   Recent company sales grow by 70%, reflecting expanded capabilities and industry recognition of VIVEbiotech’s expertise in manufacturing lentiviruses, now used in in 70% of global ex-vivo CGT clinical trials VIVEbiotech is able to manufacture integrating, and non-integrating, different pseudotypes and generations of lentiviral…